Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing surveillance of botulinum toxin type B (NerBloc) after switching from botulinum toxin type A
jRCT1080222128
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type b in cervical dystonia (CD), sponsored by Eisai Co., Ltd. Primary endpoint: Clinical condition after switch to NerBloc.
02
Drugs
botulinum toxin type b
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on jRCT1080222128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222128.